Published on Journal of Alzheimer's Disease (https://www.j-alz.com)

Home > A Phase II, randomized, double-blind, placebo-controlled study of safety, pharmacokinetics, and biomarker results of subcutaneous bapineuzumab in patients with mild to moderate Alzheimer’s disease

A Phase II, randomized, double-blind, placebo-controlled study of safety, pharmacokinetics, and biomarker results of subcutaneous bapineuzumab in patients with mild to moderate Alzheimer’s disease

Manuscript Number: 

16-0369R1

Author(s): 
Kevin Booth, H. Robert Brashear, Mark Brody, Jianing Di, Enchi Liu, Ming Lu, Richard A. Margolin, Gerald Novak, Anna Shadman, John L. Werth
Source URL: https://www.j-alz.com/manuscript-disclosures/16-0369r1